FDA DEVICE FACTS
MEDTRONIC DBS THERAPY FOR EPILEPSY
Medtronic, Inc.
Verified FDA Record identity for medical-device development research. This overview uses only fields stated in the FDA Record and is not a Device Description.医療機器開発の調査用に、確認済みの FDA Record の識別情報を示しています。この概要は FDA Record に記載された項目だけによるもので、機器説明ではありません。
Indications for use
The original PMA (P960009) for Medtronic’s Deep Brain Stimulator (DBS) System was approved on July 31, 1997 and is indicated for unilateral thalamic stimulation for the suppression of tremor in the upper extremity in patients who are diagnosed with Essential tremor or Parkinsonian tremor not adequately controlled by medications and where the tremor constitutes a significant functional disability. The SSED to support the indication is available on the CDRH website and is incorporated by reference here. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?start_search=211&ap plicant=&tradename=&productcode=&pmanumber=P960009&supplementnumber=&adv isorycommittee=&docketnumber=&supplementtype=&expeditedreview=&ivdproducts= off&combinationproducts=off&decisiondatefrom=&decisiondateto=08%2F14%2F2015
¬icedatefrom=¬icedateto=&znumber=&PAGENUM=10&sortcolumn=pn_desc_s n_desc
With the exception of the Intercept Model 37441 Patient Programmer, all components of the Medtronic DBS System for Epilepsy are approved as part of the Activa PC Neurostimulation System (P960009/S052). The Activa PC Neurostimulation System includes Activa Parkinson’s Control Therapy and Activa Tremor Control Therapy. Bilateral stimulation of the internal globus pallidus (GPi) or the subthalamic nucleus (STN) using Medtronic Activa Parkinson's Control Therapy is indicated for adjunctive therapy in reducing some of the symptoms of advanced, levodopa-responsive Parkinson's disease that are not adequately controlled with medication. Unilateral thalamic stimulation by the Medtronic Activa Tremor Control System is indicated for the suppression of tremor in the upper extremity. The system is intended for use in patients who are diagnosed with Essential Tremor or Parkinsonian tremor not adequately controlled by medications and where the tremor constitutes a significant functional disability. The current supplement was submitted to expand the indication for the Medtronic DBS System for Epilepsy.
The Medtronic DBS System for Epilepsy is indicated for the following:
Bilateral stimulation of the anterior nucleus of the thalamus (ANT) using the Medtronic DBS System for Epilepsy is indicated as an adjunctive therapy for reducing the frequency of seizures in individuals 18 years of age or older diagnosed with epilepsy characterized by partial-onset seizures, with or without secondary generalization, that are refractory to three or more antiepileptic medications.
The Medtronic DBS System for Epilepsy has demonstrated safety and effectiveness for patients who average six or more seizures per month over the three most recent months prior to implant of the DBS system (with no more than 30 days between seizures). The Medtronic DBS System for Epilepsy has not been evaluated in patients with less frequent seizures.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。